Dr. John Streicher: Reorganizing Opioid Signaling Beyond the Receptor

The dominant strategy for improving opioid therapy has been to engineer new ligands at the receptor itself — biased agonists, partial agonists, multi-target molecules. Dr. John Streicher's laboratory at the University of Arizona works a different angle. His team treats opioid signaling as a problem of circuit organization: the same kinases and second messengers produce radically different outcomes depending on how they are scaffolded inside a cell, and the chaperones that do that scaffolding are themselves druggable.

In this conversation, Dr. Streicher describes how heat shock protein 90 plays directly opposite roles in the brain and the spinal cord, why isoform-selective HSP90 inhibitors may finally solve the "brain always wins" problem of oral delivery, and how a graduate student's skeptically-received side project on intermittent fasting produced some of the strongest opioid-sparing data his lab has generated.

He came to this field because a signaling cascade felt like a puzzle he could not stop thinking about, and the puzzle has only gotten more interesting. Listeners will get a concrete look at what it means to modulate opioid pharmacology downstream of the receptor — and why the safety margins the field has been chasing for decades might actually live there.

About the Guest

Dr. John Streicher is an assistant professor in the Department of Pharmacology at the University of Arizona. His lab combines cell and molecular biology with animal pharmacology to identify new signaling regulators of the mu, delta, and kappa opioid receptors. Current lines of work include isoform-selective HSP90 inhibition as a strategy for widening the opioid therapeutic index, signal organization downstream of opioid receptors, and the unexpected effects of intermittent fasting on morphine pharmacology. Dr. Streicher trained in signal transduction during his PhD on heart failure and p38 MAP kinase, and moved into opioid pharmacology as a postdoctoral fellow with Dr. Laura Bohn at Scripps Research Institute.

Scientific Themes of the Conversation

• Opioid signaling specificity as a problem of circuit organization, not molecular identity

• HSP90 as a region-specific signaling scaffold — opposite roles in brain and spinal cord

• Isoform-selective chaperone inhibition as an alternative to receptor-level drug design

• The current state and replication troubles of biased agonism at the mu opioid receptor

• Downstream pharmacology as an underexplored route to safer opioid therapy

• Intermittent fasting as a metabolic modulator of opioid antinociception and reward

Key Insights from the Conversation

Specificity lives in circuit architecture, not in the kinase itself. ERK MAP kinase is Dr. Streicher's recurring example: the same molecule promotes opioid antinociception in one context, drives chronic pain in another, and functions as a mitogen in cancer. You cannot explain specificity by assuming each node does one thing. What differs is how scaffold proteins localize the kinase into distinct submolecular circuits. He teaches his students to think of kinases as components — a diode in a radio and a diode in a nuclear bomb can be identical — and the organization around them decides the outcome.

HSP90 runs opposite programs in brain and spinal cord. In the brain, HSP90 promotes ERK activation downstream of the mu opioid receptor and is required for antinociception. In the spinal cord, the same chaperone acts as a brake on ERK activation. Block it spinally and the dorsal horn lights up with phospho-ERK in response to opioid, routing through RSK1/2 to stronger pain relief. Block it in the brain and antinociception collapses. This is not a quirk — it is the central clue the lab has built a therapeutic strategy around.

The "brain always wins" problem is solved by isoform selectivity, not by dose. With a non-selective HSP90 inhibitor given systemically, the brain effect dominates and pain relief is lost. But the brain only uses HSP90α in this context, while the spinal cord recruits α, β, and GRP94. Collaboration with Dr. Brian Blagg at Notre Dame on β-and-GRP94-selective compounds has produced proof-of-concept IV data that reproduces the spinal-cord benefits — more potent morphine, reduced tolerance — without the brain blockade. The route from "intrathecal only" to "oral pill" runs through isoform selectivity.

Biased agonism is in a harder place than the field often acknowledges. TRV-130 was denied FDA approval for lack of clear safety advantage. A phospho-null mu knock-in mouse from Stephan Schulz's group showed reduced tolerance but no respiratory-depression benefit. Attempts to replicate the arrestin-knockout phenotypes on clean mouse backgrounds have failed. Dr. Mary Canals' group has argued that some of the apparent bias benefits may actually reflect low intrinsic efficacy. Dr. Streicher calls himself an "informed outsider" on bias now, but his read is that the field needs deeper mechanism before the strategy can be rescued.

A student's side project erased morphine reward. Graduate student David Duran wanted to test intermittent fasting in mice. Dr. Streicher was skeptical but gave the project room. The result: a six-hour feeding window for seven days increased morphine's antinociceptive efficacy in multiple pain models, strongly reduced tolerance and constipation, and completely blocked morphine reward in conditioned place preference. Receptor signaling assays showed efficacy shifts in the spinal cord and tolerance attenuation in the periaqueductal gray. The paper is published in Pain, and the translational path is unusually short — you don't need a ten-year IND process to test a feeding schedule in patients.

Do not pursue something "completely novel" as a junior scientist. HSP90 in opioids was far enough off the beaten path that Dr. Streicher spent years fielding reviewer skepticism — no one has studied this, is this even real? His retrospective advice is to pick something novel but "still in the tent" — close enough to what the field recognizes that you earn credibility before trying to chase the real heresies. The lesson is not to play it safe; it is that unfamiliarity costs you credibility before your data can speak.

Broad targets are not automatically undruggable. HSP90 is 2–3% of the protein content of every eukaryotic cell. A trained pharmacologist's first instinct is that the side effect burden would be crushing. But second-generation pan-HSP90 inhibitors have shown acceptable tolerability in oncology trials, Dr. Brian Blagg's KU-32 actually promotes neuronal survival in diabetic peripheral neuropathy and is now in Phase 1, and isoform selectivity narrows the footprint further. Dr. Streicher argues the field's default assumption — pick a low-expression, tissue-restricted target — is more habit than rule.

Episode Timeline

Timestamps were generated using AI for readability.

• 00:00 Introduction

• 01:22 Meet Dr. John Streicher

• 01:49 From heart failure to opioids — a path through signaling

• 07:49 Why the mu receptor still anchors his lab

• 09:51 The specificity puzzle — why ERK does a million things

• 13:31 What happened to biased agonism — replications in trouble

• 19:08 What's missing, and why HSP90 flips in the spinal cord

• 28:44 The "brain always wins" problem and isoform selectivity

• 33:05 HSP90 as Pac-Man — co-chaperones and the AHA1 clue

• 38:52 Picking projects that are "novel but in the tent"

• 47:25 The student's side project that blocked morphine reward

• 59:52 Running a lab through the first months of COVID

Selected Quotes

About this episode

Our guest in this episode of the Dr.GPCR podcast is Dr. John Streicher from the department of pharmacology at the University of Arizona. John started grad school in 1999 and spent some time figuring out what he was interested in. It turns out that it was signal transduction, and he worked on the signaling cascades involved in heart failure. His encounter and interest in signaling in the context of GPCRs during his postdoctoral training in Dr. Laura Bohn’s lab at Scripps Research Institute in Florida. Today, John and his team focus on understanding how signal transduction cascades downstream of the opioid receptors work, including the unique organization of chaperone protein Hsp90 modulation of opioid signaling in the brain versus the spinal cord.

Dr. John Streicher on the web

• University of Arizona

• Department of Pharmacology

• Google Scholar

• Pubmed

• LinkedIn

• Dr. GPCR Ecosystem